For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The global Intravenous Immunoglobulin (IVIg) market size was valued at USD 13315.76 Million in 2022 and will reach USD 24771.66 Million in 2028, with a CAGR of 10.9% during 2022-2028.
Intravenous Immunoglobulin (IVIG) is a solution of highly purified Immunoglobulin G, derived from large pools of human plasma that contain antibodies against a broad spectrum of bacterial and viral agents.
Influence of COVID-19 Outbreak on Intravenous Immunoglobulin (IVIg) Industry Development
After the epidemic is over, the people will have higher demand for health management and healthcare, which will promote the growth of medical consumption and open up the market from the demand side.
Immunity is a very important condition when fighting against COVID-19. Through this epidemic, the public's attention to immunity has increased significantly, and the awareness of disease prevention, early medical treatment, treatment methods and drugs, disease prognosis and harm has also been deeper, and the research and development of related drugs and reagents is bound to receive more attention. This will enable the Intravenous Immunoglobulin (IVIg) industry to attract more attention, promote product innovation and development, and stimulate market vitality. It is expected that more pharmaceutical companies will strengthen the R&D and manufacturing of such drugs.
The new crown epidemic has caused the current global plasma collection stations to basically stop the plasma donation. Due to the quarantine period, the stock of plasma must be qualified again after 3 months before it can be put into plasma production. If the epidemic control in European and American countries continues to be unclear, the resumption of pulp mining will become more difficult, which will lead to insufficient supply of pulp. In such a situation where demand exceeds supply, the price of Intravenous Immunoglobulin (IVIg) products will rise rapidly in the short term.
Strength
Rising in the prevalence of immunodeficiency diseases.
Development of cost-Effective therapeutics through large-scale production.
The rapid technological progress of IVIG products.
Huge distribution channels also promote the development of the market.
Weakness
High cost of therapy.
Fierce competition.
Opportunity
Development of the health care infrastructure.
Increasing global population aging.
Developing countries in the Asia-Pacific region, such as China and India, have huge potential markets.
Threat
Stringent government regulations.
Negative effects of the economic downturn.
Tax changes that affect profits or business models.
Region Overview:
North America had the highest growth rate of all regions.
Company Overview:
CSL Behring Biopharmaceuticals Ltd. is one of the major players operating in the Intravenous Immunoglobulin (IVIg) market, holding a share of 16.75% in 2020.
CSL Behring develops, manufactures, and markets protein-based therapies. The Company offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing plasma-derived and recombinant therapies.
Grifols develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
Segmentation Overview:
Among different product types, IVIg Liquid segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Autoimmune Disease segment occupied the biggest share from 2017 to 2022.
The Intravenous Immunoglobulin (IVIg) market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types, applications, players, 5 major regions and sub-division of major countries, and sometimes end user, channel, technology, as well as other information individually tailored before order confirmation.
Meticulous research and analysis were conducted during the preparation process of the report. The qualitative and quantitative data were gained and verified through primary and secondary sources, which include but not limited to Magazines, Press Releases, Paid Databases, Maia Data Center, National Customs, Annual Reports, Public Databases, Expert interviews, etc. Besides, primary sources include extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs, and marketing executives, downstream distributors, as well as end-clients.
In this report, the historical period starts from 2018 to 2022, and the forecast period ranges from 2023 to 2028. The facts and data are demonstrated by tables, graphs, pie charts, and other pictorial representations, which enhances the effective visual representation and decision-making capabilities for business strategy.
Key Companies in the global Intravenous Immunoglobulin (IVIg) market covered in Chapter 4:
Shanghai RAAS Blood Products Co. Ltd.
LFB group
Baxter International Inc.
ADMA Biologics, Inc.
Octapharma
Grifols
CSL Behring
Kedrion Biopharma Inc.
Takeda Pharmaceuticals Hualan Biological Engineering Inc.
China Biologics Products, Inc.
In Chapter 12 and Chapter 14.1, on the basis of types, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2028 is primarily split into:
IVIg Liquid
IVIg Powder
In Chapter 13 and Chapter 14.2, on the basis of the Downstream Industry, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2028 covers:
Immunodeficiency
Autoimmune Disease
Acute Infection
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, history and forecast (2018-2028) of the following regions are covered in Chapters 6, 7, 8, 9, 10, 11, 15:
North America (United States, Canada, Mexico)
Europe (Germany, United Kingdom, France, Italy, Spain)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina)
Middle East & Africa (Saudi Arabia, UAE, South Africa)
Outline:
Chapter 1 begins with the Intravenous Immunoglobulin (IVIg) market scope and definition, product segment introduction, global overall market size, as well as market dynamics scenarios such as opportunities, challenges, and industry development trends under inflation. It offers a high-level view of the current state of the Intravenous Immunoglobulin (IVIg) market and its likely evolution in the short to mid-term and long term.
Chapter 2 provides Intravenous Immunoglobulin (IVIg) industry chain analysis, covering raw materials analysis, cost structure, price estimate, and forecast, along with price-impacting factors, downstream channels, and major customers. It aims to help readers to grab insights into product upstream, midstream, and downstream fields.
Chapter 3 depicts Intravenous Immunoglobulin (IVIg) industry competitive analysis regarding market concentration rate, saturation rate, feasibility analysis from new entrants, as well as substitute's status and trends. It indicates the developing space and prospects of the current industry.
Chapter 4 analyzes extensive company profiles, comprising company basic info, product or service profiles, and sales, price, value, gross, and gross margin 2018-2023. It incorporates the Intravenous Immunoglobulin (IVIg) market ranking, benchmarks, and company business portfolio.
Chapter 5 presents trade statistics of import and export volume from 2018-2023, demonstrating domestic and international market comparisons in specific countries.
Chapters 6-10 highlight Intravenous Immunoglobulin (IVIg) market status at the regional and country levels, including 5 major regions of North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The region and country list in the sample is only for reference, and it can be adjusted as required.
Chapter 11 involves geographical market figures of sales, value, market share, and growth rate. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of each specific region.
Chapters 12-13 evaluate the Intravenous Immunoglobulin (IVIg) market based on different types and applications. It focuses on sales and value of 2018-2023 from both vertical and horizontal perspectives.
Chapters 14-15 elaborate on the Intravenous Immunoglobulin (IVIg) market forecast data from 2023-2028, segmented by types and applications, regions, and major countries, helping readers to know future aspects and growth trends.
Chapter 16 ends with an elaboration of data sources and research methodology. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028